All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 650+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Johnson & Johnson lands FDA approval for multiple myeloma quadruplet combo therapy
Monoclonal antibody, combo therapy, multiple myeloma, cancer - Read more 

SanBio’s chronic motor paralysis stem cell-derived therapy nabs Japan approval
Somatic stem cell-processed product, chronic motor paralysis, traumatic brain injury - Read more

THE GOOD
Business Development

CastleVax lands $31M BARDA award to continue developing intranasal COVID-19 vaccine
COVID-19 vaccine, intranasal delivery - Read more

Chugai Pharmaceuticals buys licensing rights in Japan for Roche’s investigational breast cancer med
Small molecule, breast cancer - Read more

THE GOOD
Clinical Trials

Eisai drop more Leqembi data, making the case for long term use benefits
Monoclonal antibody, Alzheimer’s disease - Read more

AC Immune hopes they have an Alzheimer’s ace up their sleeve with their “morADCs”
Small molecule, antibody-drug conjugates, neurodegeneration, Alzheimer’s disease - Read more

Umoja Biopharma in vivo (in situ) CAR-T IND gets FDA clearance, first patient dosing EOY 2024 expected
In vivo/in situ CAR-T cell therapy, hematologic malignancies, cancer - Read more

Myeloid Therapeutics initiates Ph1 for their second in vivo CAR therapy
In vivo mRNA CAR therapy, liver cancer - Read more

ALX Oncology reports positive Ph2 topline data for gastric cancer fusion protein combo therapy
Fusion protein, combo therapy, gastric cancer - Read more

THE GOOD
Earnings & Finances

Teva Pharmaceuticals shows strong growth in Q2, raises guidance for the rest of 2024 - Read more

Daiichi Sankyo goes in further on ADCs, raises R&D spend by 30% YoY
Antibody-drug conjugate, cancer - Read more (PDF page six under "Core Operating Profit")

Takeda Pharmaceuticals’ Entyvio stands IBD ground against AbbVie’s blockbuster hopeful Skyrizi
Monoclonal antibody, ulcerative colitis, Crohn’s disease - Read more

THE GOOD
Fundraises

AIRNA $60M Series A
RNA editing therapy, Alpha-1 antitrypsin deficiency - Read more

iotaSciences equity raise (amount undisclosed)
Single-cell biology handling, single-cell cloning - Read more

Antag Therapeutics closing in on DKK 377M ($53.7M) fundraise
Obesity, weight loss - Read more [Paywall]

THE GOOD
Partnerships

AbCellera and Eli Lilly expand antibody development partnership
Therapeutic antibody, immunology, cardiovascular, neuroscience - Read more

THE GOOD
Product Launches

inFormed Consent, trifermed launch program that allows researchers to gain clinical trial participant informed consent remotely
Clinical trial, informed consent - Read more

THE GOOD
Research

IRA drug prices reducing biopharma innovation? Not the case argues one study
Inflation reduction act, drug pricing - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Zevra Therapeutics faces FDA doubts ahead of adcomm
Small molecule, Niemann-Pick disease type C - Read more [Paywall]

THE BAD
Clinical Trials

PepGen announces “positive” data; analysts are wholly unimpressed
Oligonucleotide, Duchenne muscular dystrophy (DMD) - Read more

THE BAD
Company Shutdown

Tracon Pharmaceuticals calls it quits after Ph2 flunk
Monoclonal antibody, pleomorphic sarcoma, myxofibrosarcoma, cancer - Read more

THE BAD
Earnings & Finances

EuroAPI is going through a tough “transition year”, 10% net sales slide in H1 2024
CDMO, active pharmaceutical ingredient (API) - Read more

Takeda Pharmaceuticals takes $143M impairment charge related to Ovid Therapeutics acquired epilepsy med that flunked in Ph3
Small molecule, epilepsy - Read more

Sangamo Therapeutics needs more than just a Pfizer hemophilia A gene therapy win to stay alive
Gene therapy, hemophilia A - Read more

THE BAD
Lawsuits

Sanofi goes after Sarepta Therapeutics over alleged Elevidys patent infringement
Gene therapy, Duchenne muscular dystropy (DMD) - Read more

THE BAD
Layoffs

FibroGen lead asset failure in Ph2/3 results in 75% US headcount reduction
Monoclonal antibody, pancreatic cancer - Read more

HilleVax lead asset stumble in Ph2b means 40% workforce reduction
Vaccine, norovirus - Read more

Resolve Biosciences shutters San Jose site
Spatial analysis, transcriptome - Read more [LinkedIn post source]

THE BAD
Partnerships

Lundbeck nears end of 17 year depression drug collab with Takeda Pharmaceuticals
Small molecule, antidepressant - Read more

THE BAD
Politics & Policy

Biosecure Act turns attention towards clinical trials run in Chinese military associated sites
Biosecure Act, clinical trial - Read more [Paywall]

THE BAD
Strategic Plans

GSK drops Ph2 HPV vaccine candidate due to lack of “best-in-class potential”
Adjuvanted recombinant protein vaccine, human papillomavirus - Read more

THE UGLY
Clinical Trials

MacroGenics halts Ph2 trial over safety concerns
Antibody-drug conjugate, prostrate cancer - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.